ALSO READVista Pharmaceuticals standalone net profit declines 88.76% in the March 2017 quarter Vista Pharmaceuticals to hold board meeting Vista Pharmaceuticals to hold board meeting BSE resets circuit limit of Vista Pharmaceuticals, 5 others USFDA issues warning letter to Vista Pharma for Nalgonda unit
In response to its detailed reply submitted in October 2016Vista Pharmaceuticals announced that the Company has been issued a warning letter by the United States Food and Drug Administration (USFDA), in response to its detailed reply submitted in October 2016.
The Company will respond with complete details of remedial action to USFDA before the stipulated date.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)